CVS Health Corp

CVS is earning its way back, and its finances are sound. Third-quarter adjusted operating income rose 21.2% to $4.2B, led by Aetna's margin repair, and adjusted operating income rose in every operating segment. Nine-month operating cash flow more than doubled to $15.3B, and debt fell $3.9B with no new borrowing. The weaknesses lie ahead: the pharmacy benefit segment's margin is narrowing toward a guided 2027 "trough"; the share of Medicare Advantage members in 4-star plans fell to more than 69% from more than 81%, which sets 2028 bonus payments; and the full-year cash guide implies the cash surge largely stops in the fourth quarter. A split into two companies by the first half of 2028 adds execution risk.

• Revenue was $108.4B, up 5.4%. GAAP diluted EPS was $1.68, against a $(3.13) loss a year earlier that included a $5.7B goodwill impairment. Adjusted EPS was $2.09, up from $1.60.
• At Aetna (the Health Care Benefits segment), adjusted operating income was $912M versus $314M. The medical benefit ratio, the share of premiums spent on care, fell to 91.3% from 92.8%.
• 2026 guidance rose:
• adjusted EPS to at least $8.20, from $7.90–$8.10;
• operating cash flow to at least $15.5B, from at least $11.5B;
• GAAP EPS to at least $6.98, from $6.84–$7.04, so the new floor sits below the old top.
• On November 4, 2026, CVS announced a plan to split into a healthcare solutions company (Aetna, Caremark, Specialty, Oak Street, Signify) and CVS Pharmacy. The split is intended to be tax-free and is expected in the first half of 2028.
• Legal developments:
• the FTC proposed a settlement in July 2026, pending a final order;
• the Omnicare bankruptcy agreements were approved in August 2026, bringing a $193M guarantee charge;
• a $315M controlled-substances settlement was executed in October 2026, already accrued.

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

• Aetna's margin repair drives the rebound, and the guide embeds a seasonal fourth-quarter loss
• Medicare star ratings slipped, a dated headwind to 2028
• The pharmacy benefit business is losing margin, by management's own outlook
• Cash generation is strong but flattered by timing
• The split turns a third of pharmacy revenue into an inter-company contract

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what CVS files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on CVS say?” Add Viridis to Claude, or to ChatGPT.